I-BET-762: Selective BET Bromodomain Inhibitor for Inflammation and Cancer Research

Executive Summary: I-BET-762 (SKU B1498) is a highly selective inhibitor of BET family proteins, with IC₅₀ values between 32.5 and 42.5 nM and K_d values between 50.5 and 61.3 nM, demonstrating nanomolar affinity for the acetyl-lysine binding pocket of BET bromodomains (APExBIO product page). It competitively displaces acetyl-lysine, showing minimal off-target activity against other bromodomain-containing proteins (Fan et al., 2024). Functional studies confirm that I-BET-762 downregulates LPS-induced cytokine expression and promotes ferroptosis in cancer cell lines by modulating ROS and FSP1 pathways (Fan et al., 2024). The compound is insoluble in water but dissolves in DMSO (≥21.19 mg/mL) and ethanol (≥13.93 mg/mL with ultrasonication), and is stable at -20°C. Its utility spans inflammation research, epigenetic regulation studies, and cancer biology, with robust performance in both in vitro and in vivo preclinical models (related dossier).

Biological Rationale

BET proteins, including BRD2, BRD3, BRD4, and BRDT, are epigenetic readers that recognize acetylated lysine residues on histones, thus regulating gene transcription. Dysregulation of BET proteins is implicated in inflammation, cancer, and other diseases through aberrant expression of key genes. Inhibition of BET bromodomains disrupts the recruitment of transcriptional machinery to target promoters, providing a direct mechanism to modulate pathological gene expression. Targeting the BET protein signaling pathway is validated as a strategy to attenuate LPS-inducible gene transcription and modulate tumor cell survival (Fan et al., 2024).

Mechanism of Action of I-BET-762

I-BET-762 binds to the acetyl-lysine (AcK) binding pocket of BET bromodomains with high affinity (K_d = 50.5–61.3 nM), forming a 2:1 ligand:protein complex. This competitive inhibition displaces acetyl-lysine residues, preventing BET proteins from recognizing modified histones and thus blocking downstream gene activation. Functional consequences include downregulation of LPS-inducible cytokines and chemokines, reduction in transcription of pro-inflammatory genes, and augmentation of ferroptosis in cancer cells when combined with inducers like erastin (Fan et al., 2024). I-BET-762 does not significantly inhibit non-BET bromodomains at equivalent concentrations, establishing high selectivity (APExBIO).

Evidence & Benchmarks

• I-BET-762 exhibits potent inhibition of BET bromodomains with IC₅₀ values of 32.5–42.5 nM in biochemical assays (APExBIO).
• In HEK293T and HeLa cells, I-BET-762 (2 μM, 48 h) significantly enhances erastin-induced ferroptosis by increasing reactive oxygen species (ROS) levels and downregulating ferroptosis suppressor protein 1 (FSP1) (Fan et al., 2024).
• Treatment with I-BET-762 leads to decreased expression of LPS-inducible cytokines and chemokines in mouse models, indicating robust anti-inflammatory effects in vivo (APExBIO).
• I-BET-762 is insoluble in water but dissolves at ≥21.19 mg/mL in DMSO and ≥13.93 mg/mL (with ultrasonication) in ethanol, supporting diverse experimental workflows (APExBIO).
• ChIP-seq data demonstrate that I-BET-762 reduces BRD4 binding at the FSP1 promoter, correlating with reduced expression and enhanced ferroptosis (Fan et al., 2024).

This article extends previous coverage by integrating mechanistic evidence and quantitative benchmarks from the latest peer-reviewed study, surpassing the workflow-focused guidance at I-BET-762 (SKU B1498): Practical Solutions for BET Inhibition Assays.

Applications, Limits & Misconceptions

I-BET-762 is primarily applied in research on epigenetic regulation, inflammatory pathways, and cancer biology, especially in models where BET protein signaling is pathologically activated. Its efficacy is validated in both cell-based and animal models for transcriptional regulation of LPS-inducible genes and ferroptosis induction. However, its activity is context-dependent and subject to certain limitations.

Common Pitfalls or Misconceptions

• I-BET-762 is not effective against non-BET bromodomain-containing proteins. Off-target inhibition is negligible at standard research concentrations (APExBIO).
• Solubility in aqueous buffers is limited. The compound is insoluble in water; use DMSO or ethanol (with ultrasonication) for stock solutions (APExBIO).
• Activity is reduced upon prolonged storage in solution. Prepare fresh solutions or store at -20°C for optimal results.
• Ferroptosis enhancement is cell-type specific. Not all cell lines demonstrate the same sensitivity to I-BET-762-mediated ferroptosis (Fan et al., 2024).
• Not a therapeutic agent; for research use only. Clinical utility remains investigational.

For a systems-biology and translational perspective, see I-BET-762: Next-Gen BET Inhibition in Ferroptosis and Inflammation, which this article updates by detailing quantitative benchmarks and workflow constraints.

Workflow Integration & Parameters

For cell-based experiments, I-BET-762 is typically prepared in DMSO at concentrations ≥21.19 mg/mL. For ethanol-based protocols, ≥13.93 mg/mL can be achieved with ultrasonication. The compound should be stored at -20°C and used promptly in solution to avoid degradation. Working concentrations in cell culture commonly range from 0.5 to 5 μM, with exposure times of 24–72 hours, depending on the assay endpoint.

Validated applications include cell viability assays, gene expression profiling, ChIP-seq for BRD4 occupancy, and in vivo models of inflammation or cancer. For detailed workflow optimization, refer to this practical guide, noting that the current article adds mechanistic and benchmark context for advanced research designs.

Conclusion & Outlook

I-BET-762, supplied by APExBIO, is a well-characterized, selective BET bromodomain inhibitor with robust supporting evidence for its use in transcriptional regulation, inflammation, and cancer research. Its validated mechanism, nanomolar potency, and reproducible performance in preclinical models position it as a cornerstone reagent for studies targeting BET protein signaling pathways. Future research will clarify its combinatorial utility with ferroptosis inducers and expand its translational applications (Fan et al., 2024).

For a comprehensive dossier on clinical and translational prospects, see I-BET-762: A Strategic Catalyst for Translational Advances, which this article complements with updated mechanistic insights and workflow parameters.